Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.

Abstract

BACKGROUND To determine cost-effective (CE) strategies comparing adjuvant upfront aromatase inhibitor (AI) with sequential tamoxifen (TAM) AI in postmenopausal (PM) women with breast cancer (BC). DESIGN A Markov model was constructed to calculate cumulative costs and quality-adjusted life year (QALY) gains for upfront AI and TAM-AI in a hypothetical cohort of 60-year-old PM women with BC. Costs, utilities and probabilities were derived from the literature. The hazard ratios (HRs) of AI strategies were applied to a baseline cancer recurrence risk (RR) to determine CE strategies at the $50,000/QALY gain threshold. A direct payer perspective is utilized, and costs and benefits were discounted at 3%. RESULTS Two-way sensitivity analyses are presented to determine CE strategies across a wide range of HRs and in different clinical scenarios including varying RRs (low, average, high and very high). TAM-AI is the preferred CE strategy at low and average RR, while upfront AI is CE at very high RR. The CE strategy in patients with high RR was dependent on the scenario examined. CONCLUSIONS This model may help health care providers select CE-adjuvant AI strategies in PM women with BC, until further direct evidence is available from randomized clinical trials.

Statistics

010020030020072008200920102011201220132014201520162017
Citations per Year

247 Citations

Semantic Scholar estimates that this publication has 247 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Younis2007ModelingFC, title={Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.}, author={Tallal Hussein Younis and Daniel Rayson and Ron A D Dewar and Chris Skedgel}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2007}, volume={18 2}, pages={293-8} }